Literature DB >> 19422390

The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates.

John R Atack1, Wai-Si Eng, Ray E Gibson, Christine Ryan, Barbara Francis, Bindi Sohal, Gerard R Dawson, Richard J Hargreaves, H Donald Burns.   

Abstract

BACKGROUND AND
PURPOSE: alpha5IA (3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-yl)methyloxy]-1,2,4-triazolo[3,4-a]phthalazine) is a triazolophthalazine with subnanomolar affinity for alpha1-, alpha2-, alpha3- and alpha5-containing GABA(A) receptors. Here we have evaluated the relationship between plasma alpha5IA concentrations and benzodiazepine binding site occupancy in rodents and primates (rhesus monkey). EXPERIMENTAL APPROACH: In awake rats, occupancy was measured at various times after oral dosing with alpha5IA (0.03-30 mgxkg(-1)) using an in vivo {[(3)H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester)} binding assay. In anaesthetized rhesus monkeys, occupancy was measured using {[(123)I]iomazenil (ethyl 5,6-dihydro-7-iodo-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester)} gamma-scintigraphy and a bolus/infusion paradigm. In both rat and rhesus monkey, the plasma drug concentration corresponding to 50% occupancy (EC(50)) was calculated. KEY
RESULTS: In rats, alpha5IA occupancy was dose- and time-dependent with maximum occupancy occurring within the first 2 h. However, rat plasma EC(50) was time-independent, ranging from 42 to 67 ngxmL(-1) over a 24 h time course with the average being 52 ngxmL(-1) (i.e. occupancy decreased as plasma drug concentrations fell). In rhesus monkeys, the EC(50) for alpha5IA displacing steady-state [(123)I]iomazenil binding was 57 ngxmL(-1). CONCLUSIONS AND IMPLICATIONS: Rat plasma EC(50) values did not vary as a function of time indicating that alpha5IA dissociates readily for the GABA(A) receptor in vivo. These data also suggest that despite the different assays used (terminal assays of [(3)H]flumazenil in vivo binding in rats and [(123)I]iomazenil gamma-scintigraphy in anaesthetized rhesus monkeys), these techniques produced similar plasma alpha5IA EC(50) values (52 and 57 ngxmL(-1) respectively) and that the plasma-occupancy relationship for alpha5IA translates across these two species.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422390      PMCID: PMC2721264          DOI: 10.1111/j.1476-5381.2009.00216.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography.

Authors:  G Gründer; F Yokoi; S J Offord; H T Ravert; R F Dannals; J K Salzmann; S Szymanski; P D Wilson; D R Howard; D F Wong
Journal:  Neuropsychopharmacology       Date:  1997-09       Impact factor: 7.853

2.  Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit.

Authors:  Claude M Schofield; Neil L Harrison
Journal:  Brain Res       Date:  2005-01-25       Impact factor: 3.252

3.  Single photon emission tomography measurement of benzodiazepine receptor number and affinity in primate brain: a constant infusion paradigm with [123I]iomazenil.

Authors:  M Laruelle; A Abi-Dargham; Z Rattner; M S al-Tikriti; Y Zea-Ponce; S S Zoghbi; D S Charney; J Price; J J Frost; P B Hoffer
Journal:  Eur J Pharmacol       Date:  1993-01-05       Impact factor: 4.432

4.  A new human (psycho)pharmacology tool: the multiple organs coincidences counter (MOCC).

Authors:  A Malizia; G Forse; A Haida; R Gunn; J Melichar; K Poole; D Bateman; D Fahy; L Schnorr; D Brown; C Rhodes; D J Nutt; T Jones
Journal:  J Psychopharmacol       Date:  1995-01       Impact factor: 4.153

5.  Benzodiazepine receptor binding in vivo with [3H]-Ro 15-1788.

Authors:  N E Goeders; M J Kuhar
Journal:  Life Sci       Date:  1985-07-29       Impact factor: 5.037

6.  [123I]iomazenil SPECT imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain.

Authors:  E Sybirska; J P Seibyl; J D Bremner; R M Baldwin; M S al-Tikriti; C Bradberry; R T Malison; Y Zea-Ponce; S Zoghbi; M During
Journal:  Neuropharmacology       Date:  1993-07       Impact factor: 5.250

7.  Central type benzodiazepine binding sites: a positron emission tomography study in the baboon's brain.

Authors:  P Hantraye; M Kaijima; C Prenant; B Guibert; J Sastre; M Crouzel; R Naquet; D Comar; M Maziere
Journal:  Neurosci Lett       Date:  1984-07-27       Impact factor: 3.046

8.  Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.

Authors:  Akihiro Takano; Tetsuya Suhara; Yoko Ikoma; Fumihiko Yasuno; Jun Maeda; Tetsuya Ichimiya; Yasuhiko Sudo; Makoto Inoue; Yoshiro Okubo
Journal:  Int J Neuropsychopharmacol       Date:  2004-03       Impact factor: 5.176

9.  Selective antagonists of benzodiazepines.

Authors:  W Hunkeler; H Möhler; L Pieri; P Polc; E P Bonetti; R Cumin; R Schaffner; W Haefely
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

10.  Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist.

Authors:  David J Nutt; Marie Besson; Susan J Wilson; Gerard R Dawson; Anne R Lingford-Hughes
Journal:  Neuropharmacology       Date:  2007-08-16       Impact factor: 5.250

View more
  4 in total

1.  Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.

Authors:  Sarah A Nickolls; Rachel Gurrell; Guido van Amerongen; Juha Kammonen; Lishuang Cao; Adam R Brown; Clara Stead; Andy Mead; Christine Watson; Cathleen Hsu; Robert M Owen; Andy Pike; Rebecca L Fish; Laigao Chen; Ruolun Qiu; Evan D Morris; Gang Feng; Mark Whitlock; Donal Gorman; Joop van Gerven; David S Reynolds; Pinky Dua; Richard P Butt
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

2.  Prodromal dysfunction of α5GABA-A receptor modulated hippocampal ripples occurs prior to neurodegeneration in the TgF344-AD rat model of Alzheimer's disease.

Authors:  Marcia H Ratner; Scott S Downing; Ouyang Guo; KathrynAnn E Odamah; Tara M Stewart; Vidhya Kumaresan; R Jonathan Robitsek; Weiming Xia; David H Farb
Journal:  Heliyon       Date:  2021-09-01

3.  Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man.

Authors:  Joerg F Hipp; Frederic Knoflach; Robert Comley; Theresa M Ballard; Michael Honer; Gerhard Trube; Rodolfo Gasser; Eric Prinssen; Tanya L Wallace; Andreas Rothfuss; Henner Knust; Sian Lennon-Chrimes; Michael Derks; Darren Bentley; Lisa Squassante; Stephane Nave; Jana Nöldeke; Christoph Wandel; Andrew W Thomas; Maria-Clemencia Hernandez
Journal:  Sci Rep       Date:  2021-04-08       Impact factor: 4.379

4.  Long-lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5-selective GABAA inverse agonist.

Authors:  Arnaud Duchon; Agnès Gruart; Christelle Albac; Benoît Delatour; Javier Zorrilla de San Martin; José María Delgado-García; Yann Hérault; Marie-Claude Potier
Journal:  Br J Pharmacol       Date:  2020-01-09       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.